Pharming is a type of online scam where malicious code is secretly installed on a legitimate website or network server, ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease.

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a ...

Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to ...

6 analysts have expressed a variety of opinions on Pharming PHAR over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of ...

Jefferies initiated coverage of Pharming (PHAR) with a Buy rating and $14 price target The firm believes the market is either underappreciating the Joenja opportunity treating rare disease ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Pharming Group announced promising topline results from its Phase III clinical trial of leniolisib, targeting ...

On Monday, Jefferies began coverage on shares of NASDAQ:PHAR, Pharming Group, with a positive outlook, assigning the stock a Buy rating and setting a price target of $14.00. The pharmaceutical ...

The conference call presentation is available on the pharming website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming website in the days following the call.